surpass cvot tirzepatide results Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT | Diabetes Therapy Don't Miss a Beat: SURPASS-CVOT

Conclusion Semaglutide and Tirzepatide treatment options are present as a significant advance in the field of weight management and type 2 diabetes management

Diabetologia 62 , 316 (2019) R

This journeymoving from a place of struggle and frustration to one of breakthrough and empowered supportis what so many people experience with this modern approach

Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS

When It Genuinely Doesnt Matter If youre on semaglutide and its working (meaning youre losing half a pound to three pounds a week and tolerating the medication), there is no reason to switch just because tirzepatide has better average numbers